BOLD-100 (Synonyms: NKP-1339 free base; IT-139 free base; KP-1339 free base) |
| Catalog No.GC65318 |
BOLD-100 est un agent anticancéreux à base de ruthénium. BOLD-100 est également un inhibiteur de la régulation à la hausse induite par le stress du GRP78, perturbant l'homéostasie du réticulum endoplasmique (ER) et induisant une réponse au stress ER et une réponse aux protéines dépliées (UPR). BOLD-100 interfère avec l'interaction complexe entre la réponse au stress ER, la dynamique des lysosomes et l'exécution de l'autophagie.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 783324-98-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BOLD-100 is a ruthenium-based anticancer agent. BOLD-100 also is an inhibitor of stress-induced GRP78 upregulation, disrupting endoplasmic reticulum (ER) homeostasis and inducing ER stress and unfolded protein response (UPR). BOLD-100 interferes with the complex interplay between ER-stress response, lysosome dynamics, and autophagy execution[1].
[1]. Baier D, et al. The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation. Pharmaceutics. 2022;14(2):238. Published 2022 Jan 20.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *